Skip to main content

Table 2 A comparison of clinical end-point data

From: RandomiSed clinical trial assessing Use of an anti-inflammatoRy aGent in attenUating peri-operatiVe inflAmmatioN in non-meTastatic colon cancer – the S.U.R.G.U.V.A.N.T. trial

 

Placebo (n = 28)

Taurolidine (n = 32)

p-value

Pain

Day 1

2.5

1.8

0.391

Day 2

1.9

2

0.873

Day 3

1.9

1

0.179

Time to bowel function (hrs)

 

39

34

0.32

Infective complication

 

8

4

0.19

 Surgical site infection

 

5

1

0.09

 Anastomotic leak

 

2

1

0.59

 Other

 

0

2

0.49

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us